scholarly journals A point mutation in the F1 subunit of human respiratory syncytial virus fusion glycoprotein blocks its cell surface transport at an early stage of the exocytic pathway

1996 ◽  
Vol 77 (4) ◽  
pp. 649-660 ◽  
Author(s):  
J. A. Lopez ◽  
R. Bustos ◽  
A. Portela ◽  
B. Garcia-Barreno ◽  
J. A. Melero
2006 ◽  
Vol 81 (1) ◽  
pp. 261-271 ◽  
Author(s):  
Roberta L. Crim ◽  
Susette A. Audet ◽  
Steven A. Feldman ◽  
Howard S. Mostowski ◽  
Judy A. Beeler

ABSTRACT It has been shown previously that the fusion glycoprotein of human respiratory syncytial virus (RSV-F) interacts with cellular heparan sulfate. Synthetic overlapping peptides derived from the F-protein sequence of RSV subtype A (strain A2) were tested for their ability to bind heparin using heparin-agarose affinity chromatography (HAAC). This evaluation identified 15 peptides representing eight linear heparin-binding domains (HBDs) located within F1 and F2 and spanning the protease cleavage activation site. All peptides bound to Vero and A549 cells, and binding was inhibited by soluble heparins and diminished by either enzymatic treatment to remove cell surface glycosaminoglycans or by treatment with sodium chlorate to decrease cellular sulfation. RSV-F HBD peptides were less likely to bind to glycosaminoglycan-deficient CHO-745 cells than parental CHO-K1 cells that express these molecules. Three RSV-F HBD peptides (F16, F26, and F55) inhibited virus infectivity; two of these peptides (F16 and F55) inhibited binding of virus to Vero cells, while the third (F26) did not. These studies provided evidence that two of the linear HBDs mapped by peptides F16 and F55 may mediate one of the first steps in the attachment of virus to cells while the third, F26, inhibited infectivity at a postattachment step, suggesting that interactions with cell surface glycosaminoglycans may play a role in infectivity of some RSV strains.


2012 ◽  
Vol 81 (1) ◽  
pp. 115-118 ◽  
Author(s):  
Yanpeng Zheng ◽  
Yaning Tang ◽  
Yuanhui Fu ◽  
Jinsheng He ◽  
Xiaobo Wang ◽  
...  

1989 ◽  
Vol 264 (18) ◽  
pp. 10339-10342
Author(s):  
R G Arumugham ◽  
R C Seid ◽  
S Doyle ◽  
S W Hildreth ◽  
P R Paradiso

2016 ◽  
Vol 60 (11) ◽  
pp. 6498-6509 ◽  
Author(s):  
Concepción Palomo ◽  
Vicente Mas ◽  
Laurent Detalle ◽  
Erik Depla ◽  
Olga Cano ◽  
...  

ABSTRACTALX-0171 is a trivalent Nanobody derived from monovalent Nb017 that binds to antigenic site II of the human respiratory syncytial virus (hRSV) fusion (F) glycoprotein. ALX-0171 is about 6,000 to 10,000 times more potent than Nb017 in neutralization tests with strains of hRSV antigenic groups A and B. To explore the effect of this enhanced neutralization on escape mutant selection, viruses resistant to either ALX-0171 or Nb017 were isolated after serial passage of the hRSV Long strain in the presence of suboptimal concentrations of the respective Nanobodies. Resistant viruses emerged notably faster with Nb017 than with ALX-0171 and in both cases contained amino acid changes in antigenic site II of hRSV F. Detailed binding and neutralization analyses of these escape mutants as well as previously described mutants resistant to certain monoclonal antibodies (MAbs) offered a comprehensive description of site II mutations which are relevant for neutralization by MAbs and Nanobodies. Notably, ALX-0171 showed a sizeable neutralization potency with most escape mutants, even with some of those selected with the Nanobody, and these findings make ALX-0171 an attractive antiviral for treatment of hRSV infections.


PLoS ONE ◽  
2013 ◽  
Vol 8 (5) ◽  
pp. e64012 ◽  
Author(s):  
Hsin Chi ◽  
Hsin-Fu Liu ◽  
Li-Chuan Weng ◽  
Nai-Yu Wang ◽  
Nan-Chang Chiu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document